Readers and Tweeters Diagnose Greed and Chronic Pain Within US Health Care System
Posted onKHN gives readers a chance to comment on a recent batch of stories.
KHN gives readers a chance to comment on a recent batch of stories.
The good, the bad, and the unknown about the Centennial State’s proposal to decriminalize and regulate magic mushrooms and plant-based psychedelics.
The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
The wait is nearly over for parents of kids under 5 as a key advisory committee to the FDA recommends authorizing a covid-19 vaccine for the youngest children. Meanwhile, Congress is struggling to fill in the details of its gun control compromise, and, as the Supreme Court prepares to throw the question of abortion legality back to the states, the number of abortions has been rising. Shefali Luthra of The 19th, Sarah Karlin-Smith of the Pink Sheet, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicare’s trustees board.
Two mass shootings in two weeks — one at a Texas elementary school that killed 19 fourth graders and two teachers — have reignited the “guns-as-public-health-problem” debate. But political consensus seems as far away as ever. Meanwhile, the FDA is in the congressional hot seat over its handling of the infant formula shortage. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Richard Baron, head of the American Board of Internal Medicine, about how doctors should discipline colleagues who spread medical misinformation.
Una opción inyectable mensual para el tratamiento de la adicción a opioides no logra llegar a todos los que la necesitan por las trabas burocráticas para obtener el medicamento.
In California, where overdose deaths are on the rise, physicians say administering anti-addiction medication as a monthly injection holds tremendous potential. So, why aren’t more patients getting it?
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.